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Adiponectin is one of the adipokines secreted by adipo-
cytes and regulates energy homeostasis associated with
insulin sensitivity, suggesting a possibility of nutri-
tional regulation of adiponectin gene expression. In this
study, we showed that the transcription of adiponectin
gene was induced 4–6 h after refeeding of mice. Also,
differentiated 3T3-L1 adipocytes that were treated with
high glucose expressed significantly increased adipo-
nectin mRNA. Promoter analysis using nuclear extracts
from white adipose tissue revealed that CCAAT/en-
hancer binding protein (C/EBP) and nuclear factor-Y
(NF-Y) bound on the 117/73 region of the adiponec-
tin promoter. This region was critical for the activity of
the adiponectin promoter as the deletion or mutation of
this region markedly diminished the promoter activity
to a basal level. Furthermore, the C/EBP binding in-
creased in both refed animal and high glucose–treated
3T3-L1 adipocytes in an electrophoretic mobility shift
assay, suggesting that C/EBP is responsible for the
dietary response of the adiponectin gene expression.
Chromatin immunoprecipitation studies demonstrated
the binding of C/EBP and NF-Y in both mouse and
differentiated 3T3-L1 adipocytes and also that C/EBP
binding increased in response to high glucose. These
findings demonstrated that C/EBP and NF-Y are critical
for the regulation of the adiponectin expression in
response to nutrients and in the course of adipocyte
differentiation. Diabetes 53:2757–2766, 2004
A dipose tissue, in addition to its ability to storeextra energy as triglyceride, is now consideredto be an endocrine organ performing metabolicregulation by releasing hormones in response
to changes in metabolic status (1–3). These secreted
molecules include leptin, tumor necrosis factor-, adi-
ponectin, and resistin, referred to collectively as adipo-
kines (4). Because excess or lack of adipose tissue is
associated with insulin resistance and type 2 diabetes, it
has been postulated that adipokines are possible linkers
between obesity and insulin resistance (5).
Adiponectin, also known as Acrp30, AdipoQ, apM1, and
GBP28, is a recently found adipokine that is expressed
exclusively in white adipose tissue (6–9). The plasma level
of adiponectin declined at an early phase of obesity and a
lower level was maintained after the development of type
2 diabetes in animals (10) and in humans (11,12), indicat-
ing a possible relationship with insulin resistance (13). It is
reported that adiponectin decreases insulin resistance by
increasing fatty acid oxidation and glucose transport in
muscle (14,15). Furthermore, adiponectin lowers plasma
glucose level by inhibiting endogenous glucose production
from liver (16,17). Therefore, it is likely that adiponectin is
a potent insulin enhancer linking adipose tissue and
whole-body glucose metabolism.
Although the physiological effects of adiponectin have
been investigated intensively, the molecular mechanisms
that regulate the expression of the adiponectin gene are
largely unknown. Several factors that regulate adiponectin
expression were reported, including peroxisome prolifera-
tor–activated receptor- agonist (18), tumor necrosis
factor- (19), -adrenergic stimulation (20), and insulin
(9,21). These factors are considered to regulate adiponec-
tin gene expression in response to a change in metabolic
status; however, there is little correlation for the physio-
logical regulators of adiponectin gene expression. In a
clinical study of human subjects, inverse correlations were
observed between plasma adiponectin and insulin in type
2 diabetic patients, suggesting that plasma insulin does not
independently affect adiponectin secretion (11). Another
report showed that plasma adiponectin increased post-
prandially in obese but not in lean subjects (22). In
contrast, it was also reported that refeeding of animals led
to increased expression of adiponectin along with leptin
(23). It is not clear, therefore, how adiponectin expression
and secretion are regulated by the metabolic stimulus
either in a normal or in a pathological situation.
The family of CCAAT/enhancer binding protein (C/EBP)
transcription factors are expressed in a number of tissues
and are involved in the regulation of several biological
processes, including control of energy metabolism (24–
26). Importantly, C/EBP- and - are known to be key
regulators for adipocyte differentiation (27–29) and play
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roles in the expression of adipocyte-specific genes (30,31).
In addition, C/EBPs control the synthesis of proteins that
are necessary for lipid metabolism and gluconeogenesis
(30,32), suggesting that this transcription factor may reg-
ulate the expression of genes related to energy metabolism
in adipocytes.
In this study, we investigated the molecular mechanisms
of adiponectin gene expression. The adiponectin promoter
was analyzed by a DNA-protein binding assay, showing
that the adiponectin promoter bound C/EBPs and nuclear
factor-Y (NF-Y). We also showed that C/EBPs could trans-
activate the adiponectin promoter and that NF-Y also ac-
tivated the adiponectin promoter regulating basal activity.
Moreover, we revealed that adiponectin expression, along
with C/EBP binding to its promoter, was regulated by di-
etary nutrients. These observations suggest a possible role
of C/EBP and NF-Y in the control of adiponectin expres-
sion in response to diet as well as adipocyte differentiation.
RESEARCH DESIGN AND METHODS
Plasmids. Mouse adiponectin promoter spanning 1,138 to 30 bp was
amplified by PCR and ligated with luciferase vector to generate pGLB-A-1138.
5-Serial deletion constructs (pGLB-A-727, pGLB-A-502, pGLB-A-202, pGLB-A-
134, and pGLB-A-57) were generated by deletion using restriction enzymes.
Mutant constructs (pGLB-A-134m1, pGLB-A-134m2, pGLB-A-134m3, pGLB-A-
134m4, pGLB-A-134m5, and pGLB-A-134m45) were produced by site-directed
mutagenesis. Plasmid pmYA (4YA13 m29), which encodes the dominant
negative form of the A subunit of NF-Y, was provided by Dr. R. Mantovani
(University of Milan, Milan, Italy) (33). Expression plasmids pCMV-rC/EBP-
and pCMV-mC/EBP- were gifts from Dr. J.R. Cardinaux (Centre de Neuro-
sciences Psychiatriques, Lausanne, Switzerland).
Adipocyte differentiation. 3T3-L1 preadipocytes were maintained in Dul-
becco’s modified Eagle’s medium (DMEM) that contained 10% FBS. For
inducing differentiation, 2-day postconfluent cells (designated day 0) were fed
DMEM that contained 10% FBS, 0.5 mmol/l 3-isobutyl-1-methyl-xanthine, 1
mol/l dexamethasone, and 1.67 mol/l insulin until day 2. Cells then were fed
DMEM supplemented with FBS/insulin for 2 days, after which they were fed
every other day with DMEM that contained FBS. For investigating the effect of
glucose or fatty acid, day 6–8 cells were maintained with DMEM that con-
tained low glucose (5.5 mmol/l) and 10% FBS 24 h before treatment.
Northern blot analysis and RT–PCR. Total RNA was extracted using TRIzol
reagent. Ten micrograms of total RNA of each group was subjected to
electrophoresis and transferred to nylon membrane for hybridization. For
RT-PCR, 5 g of total RNA was reverse transcribed, and the resulting cDNAs
were used as a template for PCR. The sequences used for RT-PCR are as
follows: adiponectin, 5-AGCCT GGAGA AGCCG CTTAT-3, 5-TTGCA GT
AGA ACTTG CCAGT GC; resistin, 5-TCAAC TCCCT GTTTC CAAAT GC-3,
5-TCTTC ACGAA TGTCC CACGA; aP2, 5-GATCG GATCC ACCAT GTGTG
ATGCC TTTGT GGGAA CC-3, 5-GATCC TCGAG TCATG CCCTT TCATA
AACTC TTGT-3; glyceraldehyde-3-phosphate dehydrogenase, 5-ACCAC AG
TCC ATGCC ATCAC-3, 5-TCCAC CACCC TGTTG CTGTA-3.
Nuclear extract preparation. Nuclear extract preparation protocol was
modified from the description by Lavery et al. (34). Rat epididymal adipose
tissues were homogenized with 0.3 mol/l sucrose buffer (15 mmol/l HEPES
[pH 7.9], 60 mmol/l KCl, 15 mmol/l NaCl, 0.15 mmol/l spermine, 0.5 mmol/l
spermidine, 0.3 mol/l sucrose, 0.5 mmol/l dithiothreitol [DTT], 0.5 mmol/l
phenylmethylsulfonyl fluoride [PMSF], and 5 g/ml protease inhibitor cock-
tail). The cell lysate was filtered through gauze and added on the 0.9-mol/l
sucrose buffer for nuclear isolation. The nucleus was pelleted by centrifuga-
tion at 3,000 rpm for 5 min and resuspended in nuclear storage buffer (20
FIG. 1. Transcription of adiponectin is
regulated by adipocyte differentiation
and nutrient. A: Adiponectin expression
in 3T3-L1 cells at different differentia-
tion stages. 3T3-L1 preadipocytes at 2
days postconfluent state were induced
to differentiation, and total RNA was
isolated at 0, 1, 2, 4, and 6 days after the
induction of differentiation. Glyceralde-
hyde-3-phosphate dehydrogenase as in-
ternal control. B: Northern blot of
adiponectin mRNA in 3T3-L1 adipocytes
in response to glucose. Fully differenti-
ated 3T3-L1 adipocytes were treated
with glucose (27.5 mmol/l) for 0, 4, 12,
and 24 h after incubation in low glucose
(5.5 mmol/l) for 24 h. Total RNA was
prepared and subjected to Northern
blot using specific cDNA probe for adi-
ponectin and -actin. C: Adiponectin
expression in adipose tissues according
to fasted and refed state. For each
group, four mice were fasted for 48 h
and refed with normal diet for indicated
hours. Total RNA of adipose tissue was
prepared and subjected to RT-PCR. D:
Schematic representation of RT-PCR re-
sult shown in C by densitometry. The
density of each band was quantified by
densitometer and normalized by glycer-
aldehyde-3-phosphate dehydrogenase
result.
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mmol/l Tris-HCl [pH 7.9], 75 mmol/l NaCl, 0.5 mmol/l EDTA, 0.85 mmol/l DTT,
and 0.125 mmol/l PMSF). After a brief centrifugation, the pellet was resus-
pended in 1 NUN buffer (1 mol/l urea, 0.3 mol/l NaCl, 1% Nonidet P-40, 25
mmol/l HEPES [pH 7.6], and 1 mmol/l DTT) and shaken for 30 min for
extraction of nuclear protein. The protein concentration was determined by
the Bradford method (35). For extracting nuclear proteins from cultured cells,
the harvested cells were resuspended in Buffer A (10 mmol/l HEPES [pH 7.9],
10 mmol/l KCl, 0.1 mmol/l EDTA, 0.1 mmol/l EGTA, 1 mmol/l DTT, and 0.5
mmol/l PMSF). After 15 min of incubation on ice, 1:20 volume of 10% Nonidet
P-40 was added, vortexed, and then centrifuged. The next steps were the same
as those for adipose tissue.
DNase I footprinting assay. The promoter region of the adiponectin gene
covering from 256 to 30 bp was labeled and bound with 60 g of nuclear
extract. After 30 min of incubation on ice, DNase I was treated for 2 min. The
reactions were purified and analyzed on a 6% denatured polyacrylamide gel. A
G	A ladder was prepared by using the same labeled fragment and was run on
the same gel.
Electrophoretic mobility shift assay. The probes corresponding to region
AII were generated as follows: 10 pmol of single-stranded sense oligonucleo-
tides were labeled and annealed with 5 mol/l excess of antisense oligonucle-
otides. The probes encompassing 121 to 63 of promoter used in the
mutation study were generated by PCR, using 32P-labeled antisense primer
(80 to 63) and unlabeled sense primer (121 to 104) and pGLB-A-134
and corresponding mutant constructs as templates. Probes were incubated
with nuclear extract for 15 min on ice, and the DNA-protein complexes were
resolved on 4% polyacrylamide gel. Competitive and supershift assays were
performed by adding 100 mmol/l excess of unlabeled oligonucleotides or 2 g
of antibodies, respectively. The oligonucleotides used as competitors are as
follows: GATA, 5-CACTT GATAA CAGAA AGTGA TAACT CT-3; LDL-R
sterol-response element (SRE), 5-TTTGA AAATC ACCCC ACTGC AAAC-3;
NF-Y, 5-AGACC GTACG TGATT GGTTA ATCTC TT-3; C/EBP, 5-TGCAG
ATTGC GCAAT CTGCA-3; and AP-1, 5-CGCTT GATGA GTCAG CCGGA A-3.
Western blot analysis. Fifteen micrograms of nuclear extract was mixed in
sample buffer, incubated at 95°C, and separated by 12% SDS–PAGE. The
specific proteins were detected by enhanced chemiluminescence for 1 min.
Equal protein loading was confirmed by staining with Coomassie Brilliant
G-250.
Chromatin immunoprecipitation assay. The chromatin immunoprecipita-
tion (ChIP) assay protocol was modified from the description by Latasa et al.
(36). Briefly, mice were perfused and fixed with formaldehyde, and adipose
tissues were homogenized and sonicated. The resulting supernatant was
divided into aliquots for 10-fold dilution in ChIP dilution buffer and precleared
with protein A–agarose that contained salmon sperm DNA for 1 h. The
antibodies were added and incubated for 12–18 h at 4°C, and the complexes
were collected with 50% slurry of protein A–agarose for 3 h. The beads were
washed, and chromatin complexes were eluted from the beads. After reverse
of the cross-linking, DNA was purified, and 4 l of input control or ChIP
samples was used as a template in PCR using the primer sets for region AII
(5-AGAAG CTCTA CTTGG CTTCC CAGAC CCAAG CTGGA-3, 5-GCAGA
CCCCA GCTTA CCA-3) or for exon 3 region (5-AGCCT GGAGA AGCCG
CTTAG-3, 5-TTGCA GTAGA ACTTG CCAGT GC-3), respectively. In the
experiments using 3T3-L1 cells, 
1  106 differentiated adipocytes were fixed
with formaldehyde, harvested, and then sonicated as described above.
Transient transfection. Transient transfections were performed using Lipo-
fectamine reagent (Invitrogen) according to the manufacturer’s protocol.
Luciferase activities were measured using 10 l of cell extract and 50 l
of luciferase assay reagent. -Galactosidase activity was measured for
normalization.
RESULTS
Adiponectin gene expression during adipocyte differ-
entiation and its regulation by nutrition. To investi-
gate the regulation of adiponectin gene expression, we
first examined the adiponectin mRNA level during adipo-
cyte differentiation of 3T3-L1 fibroblasts. Total RNA was
extracted from different stages of the cells after differen-
tiation and subjected to RT-PCR. As shown in Fig. 1A,
FIG. 2. Nuclear protein binding sites in the
mouse adiponectin promoter. A: DNase I foot-
printing assay of the proximal adiponectin pro-
moter. The mouse adiponectin promoter
fragment from 256 to 21 bp was end labeled
and used for DNase I footprint analysis with the
nuclear extract of rat liver or white adipose
tissue (WAT). Three regions (AO, AI, and AII)
were protected by liver nuclear extracts, of
which only region AII was protected by nuclear
extract of white adipose tissue. B: Sequence
analysis of region AII (117/73). One CCAAT
box and two inverted Y-boxes are marked. Two
possible C/EBP binding sites were indicated.
For comparison, human DNA sequence of the
same region was presented, and identical se-
quences were marked by .
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adiponectin mRNA was not detected in preadipocyte but
started to be induced at 4 days after induction of differen-
tiation and elevated further until 6 days, which is consis-
tent with the previous reports (6,9). Meanwhile, resistin
appeared earlier than adiponectin and continued to in-
crease until 6 days after differentiation. Another adipo-
cyte-specific gene, aP2, was slightly expressed in the
preadipocyte, and the expression level almost reached the
maximum level at day 2. This indicates that adiponectin is
expressed only in fully differentiated adipocytes compared
with other adipocyte-specific genes, aP2 and resistin. On
the basis of this result, we used differentiated adipocytes
of at least day 6 for the next experiment to investigate
nutritional regulation.
Next, we examined the effect of glucose on the expres-
sion of adiponectin. Differentiated 3T3-L1 adipocytes were
maintained in media that contained 5.5 mmol/l glucose for
24 h and then were treated with 27.5 mmol/l glucose.
Northern blot analysis showed that treatment with a high
concentration of glucose for 24 h drastically upregulated
adiponectin expression (Fig. 1B), suggesting that tran-
scription of adiponectin is induced by glucose. This result
led us to investigate whether adiponectin expression could
be regulated in response to diet in living organisms. Mice
were fasted and then refed a standard diet for 2–8 h, and
the adiponectin expression was examined by RT-PCR. As
shown in Fig. 1C and D, the expression was induced and
peaked 4–6 h after refeeding, suggesting that the adi-
ponectin expression is regulated by diet at the transcrip-
tional level in the early phase of refeeding.
Localization of protein binding sites in adiponectin
promoter. To identify cis-acting elements responsible for
the regulation of adiponectin gene expression, we per-
formed DNase I footprinting analysis using nuclear extract
from white adipose tissues. The DNA fragments covering
the proximal 500-bp region of the promoter were sub-
cloned and used as probes. When liver nuclear extract was
used as control because of its abundance of transcription
factors, several protein binding site regions (AO, AI, and
AII; Fig. 2A) were protected. However, when nuclear
extract from adipose tissue was used, only region AII was
clearly protected. Region AII has one CCAAT box and two
inverted Y boxes, and, interestingly, potential C/EBP bind-
ing sites are located between them. Figure 2B shows the
sequence of AII with potential nuclear protein binding
sites. When it was compared with the human sequence,
only the proximal CCAAT box and C/EBP site showed high
sequence similarity between species.
Determination of the transcription factors bound to
region AII. For investigating the binding of protein to
region AII of the adiponectin promoter, a electrophoretic
mobility shift assay (EMSA) was performed using nuclear
extract from white adipose tissue. The oligonucleotide
probe of the region AII sequence formed two major com-
FIG. 3. NF-Y and C/EBP are bound to the adiponectin promoter in vitro. A: EMSA of region AII using nuclear extracts of rat white adipose tissue.
The oligonucleotide covering region AII (117/73) was used as probe. 32P-labeled double-stranded oligonucleotide (50,000 cpm) was incubated
with nuclear extract. Unlabeled double-stranded oligonucleotides known as consensus sequences of NF-Y, GATA, C/EBP, SRE, and AP-1 were
added to the reaction mixture in 100 mmol/l excess (lanes 3–7). B: Supershift assay of region AII. Two micrograms of antibodies against NF-YA,
NF-YB, NF-YC, C/EBP-, or C/EBP- were incubated with reaction mixture before adding labeled probe.
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plexes, slow-migrating bands and a fast-migrating band
(Fig. 3A). For determining which transcription factors are
involved in these DNA-protein complexes, unlabeled com-
petitor oligonucleotides for NF-Y, GATA, C/EBP, SRE, and
AP-1 were added to the reaction. As shown in Fig. 3A, the
addition of NF-Y and C/EBP competitors abolished the
binding of slow- and fast-migrating bands, respectively,
whereas unlabeled GATA, SRE, and AP-1 oligonucleotides
did not affect the complex formation. The binding of NF-Y
and C/EBP to region AII was further investigated by a
supershift assay. As shown in Fig. 3B, the DNA-protein
complexes were supershifted by anti–NF-YA, NF-YB,
C/EBP-, and C/EBP-, indicating that both NF-Y and
C/EBP bind to region AII of the adiponectin promoter.
Effect of site-specific mutations on C/EBP and NF-Y
binding activity. For further investigation of precise
binding sites of C/EBP and NF-Y, several mutant oligonu-
cleotide probes were generated (Fig. 4A) and EMSA was
carried out. Given that 293T cells express only a trace
amount of endogenous C/EBPs, nuclear extracts from
293T cells that overexpress C/EBP- or C/EBP- were
used to examine specific binding activities of C/EBP- and
C/EBP- to adiponectin promoter. The overexpression of
each transcription factor was confirmed by Western blot
(Fig. 4C). As shown in Fig. 4B, C/EBP- (lane 7) and
C/EBP- (lane 13) bound to the wild-type oligonucleotide
probe. However, binding activities of C/EBP- and C/EBP-
diminished when m4 mutated oligonucleotide was used as
a probe (lanes 11 and 17). With nuclear extract from 293T
cells, which do not express C/EBP, only NF-Y binding was
observed (lane 1); however, this binding was almost
diminished when the m5 probe was used (lanes 6, 12, and
18). It is interesting that the m4 mutation also caused the
attenuated binding of NF-Y (lane 5), and, conversely,
C/EBP binding was greatly affected by the mutation of the
m5 region. It is acceptable because the potential C/EBP
binding site expands the m4 and m5 regions, but it is not
excluded that a certain form of the interaction is required
for full binding of two transcription factor families from
this result. When unlabeled mutated oligonucleotides were
used as competitors, binding of C/EBP- and C/EBP-
decreased by the addition of the m5 competitor (Fig. 4D,
lane 3) as well as the m4 competitor (lane 4). These
findings suggest that C/EBP- and C/EBP- bound to
adiponectin promoter via the m4 and m5 regions, whereas
FIG. 4. Effect of site-specific mutations on
C/EBP and NF-Y binding activity. Nuclear ex-
tracts were prepared from 293T cells overex-
pressing C/EBP- or -. For mock, the cells were
transfected by pcDNA. All probes were gener-
ated by PCR with 32P-labeled antisense primer
and unlabeled sense primers using site-directed
mutated plasmids as templates, and purified
from the polyacrylamide gel, to equalize the
specific activities between probes. A: DNA oli-
gonucleotide sequence of wild and mutated
probes used in EMSA. Mutated regions are indi-
cated by lowercase with with their name. B:
EMSA using nuclear extracts of 293T cells over-
expression C/EBP- and C/EBP-. Wild-type
(wt) and mutant (m1, m2, m3, m4, and m5)
probes were incubated with 4 g of indicated
nuclear extracts. The bands corresponding to
NF-Y, C/EBP-, and C/EBP- are marked by
arrows. C: Western blot (WB) analysis of
C/EBP- and - for validating the expression of
C/EBP- and -. 293T cells were transfected
with expression vectors for C/EBP- or - and
harvested 48 h after transfection, and nuclear
extracts from the cells were subjected to SDS-
PAGE. D: Competition assay of AII probe. Nu-
clear extracts prepared from rat white adipose
tissue (WAT) were incubated with wild-type AII
probe with or without indicated mutated oligo-
nucleotides as cold competitors.
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NF-Y bound via the m5 region, and also suggest that NF-Y
binding is required for the full binding activities of C/EBPs.
C/EBPs activate adiponectin promoter. For determin-
ing whether NF-Y and C/EBP are able to regulate adipo-
nectin promoter activity, the adiponectin promoter (1,138/
30) linked to the luciferase reporter vector was construct-
ed and its responsiveness to C/EBPs and NF-Ys was
tested. The reporter construct was transiently transfected
into CV-1 cells in the presence or absence of expression
plasmids of NF-YA, NF-YB, NF-YC, C/EBP-, or C/EBP-.
As shown in Fig. 5A, C/EBP- and C/EBP- activated
adiponectin promoter activities, whereas NF-Ys could not.
Because NF-Y is constitutively expressed in all eukaryotic
cells and is composed of three different subunits, YA, YB,
and YC, which are collectively required to bind to the
sequence (37), it was thought that overexpression of
individual NF-Y subunits probably did not affect the pro-
moter activities. So we tested the response to the domi-
nant negative mutant of NF-YA. The promoter activity was
markedly inhibited to 20% of basal promoter activity
when cotransfected with the dominant negative form.
Taken together, these results suggest that C/EBPs upregu-
late adiponectin promoter, whereas NF-Y has a crucial
role in maintaining basal adiponectin gene expression.
Binding of C/EBP and NF-Y at region AII plays a
crucial role in adiponectin promoter activities. Next,
we generated a series of plasmid constructs that contained
5 serial deletion constructs shown in Fig. 6A and trans-
fected into 3T3-L1 adipocytes. As shown in Fig. 6B, the
adiponectin promoter activity decreased dramatically
when up to 57 bp was deleted, demonstrating that the
134/57 region is critical and sufficient for the promoter
activity. Moreover, the C/EBP responsiveness was signifi-
cantly decreased between 134 and 57 (Fig. 6C), so we
concluded that the most proximal 134 bp of the promoter
has a functional C/EBP site, taken together with the
mutation EMSA study shown in Fig. 4. We also investi-
gated the influence of the mutations used for the EMSA
study on the C/EBP transactivation property. When the m4
or m5 mutation, which proved to be important for the
C/EBP binding on the EMSA, was introduced into the
134 construct, C/EBP responsiveness was greatly re-
duced (Fig. 6D). This effect was more apparent when m4
and m5 mutations were introduced simultaneously, sug-
gesting that the C/EBP and NF-Y sites on region AII are
functional and necessary for the stimulation of the adi-
ponectin promoter.
Binding of C/EBP and NF-Y is affected by dietary
status. Because the adiponectin expression was regulated
by diet as shown in Fig. 1, we examined whether the
binding of NF-Y and C/EBP could be changed according to
the dietary status. Nuclear extracts from white adipose
tissues of fasted or refed rats were prepared and examined
by EMSA. As shown in Fig. 7A, the dietary intakes in-
creased the complex formation on the region AII probe. To
confirm the binding activities of C/EBP, we incubated
nuclear extracts at 72°C for 20 min before the binding
reaction because C/EBP has heat-stable characteristics
(38). The result clearly showed the increase of binding of
the heat-stable factor, supposed to be C/EBP, to region AII
(Fig. 7A). Therefore, it is likely that C/EBP is responsible,
in part, for the increased expression of the adiponectin
gene 
6 h after refeeding, as shown in Fig. 1 by the
increased binding to region AII.
Next, we tested whether C/EBP binding is increased in
response to glucose in differentiated 3T3-L1 adipocytes.
Nuclear extracts were prepared from fully differentiated
adipocytes that were maintained in media that contained
5.5 mmol/l glucose for 24 h and then treated with 27.5
mmol/l glucose. As shown in Fig. 7B, C/EBP binding was
apparently increased 12 h after glucose treatment, simi-
lar to the result in refed animals (Fig. 7A). Thus, taken
together with the result shown in Fig. 1B, it is concluded
FIG. 5. Response of adiponectin promoter to NF-Ys and C/EBPs in CV-1 cells. A: A construct consisting of1,138 bp of 5-flanking sequences from
the mouse adiponectin gene was inserted into luciferase reporter vector and transiently cotransfected into CV-1 cells in the presence or absence
of expression vectors (0.1 g) encoding NF-YA, NF-YB, NF-YC, C/EBP-, and C/EBP-, respectively. Luciferase activity was measured 48 h after
transfection. Data represent relative luciferase activity (means  SD) of three independent experiments. B: CV-1 cells were transfected with
pGLB-A-1134 in the presence or absence of dominant negative mutant of NF-YA (0.1 g). Luciferase activities were measured 48 h after
transfection and normalized by -galactosidase activity. Data represent means  SD of three independent experiments.
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that the C/EBP binding is responsible for the glucose
induction of adiponectin in 3T3-L1 adipocytes.
To correlate the change of C/EBP and NF-Y levels, we
conducted Western blot analysis. As illustrated in Fig. 7C
and D, C/EBP- and C/EBP- were markedly increased by
diet or glucose, whereas NF-Y and other proteins were not
changed significantly, suggesting that dietary status regu-
lates the levels of C/EBP proteins, resulting in changes in
their binding activities.
C/EBPs and NF-Ys bind to the proximal adiponectin
promoter in vivo. To confirm whether NF-Y or C/EBP
binds directly to the adiponectin promoter in vivo, we
used chromatin immunoprecipitation analysis for the next
step. The DNA encompassing region AII was amplified by
PCR from chromatin immunoprecipitated with antibodies
against C/EBP-, C/EBP-, NF-YA, NF-YB, and NF-YC,
whereas exon 3, which is located 10 kb downstream of
region AII, was not amplified (Fig. 8B). It is interesting that
the cyclic AMP response element binding protein (CBP),
known as one of the coactivators of C/EBP, also occupied
the adiponectin promoter. These results indicate that NF-Y
and C/EBP bind directly to region AII of the adiponectin
proximal promoter in vivo and also suggest the involve-
ment of CBP as a coactivator.
Previous reports and our results in Fig. 1A showed that
adiponectin expression is induced 4 days after adipocyte
differentiation. For investigating whether the binding of
C/EBPs and NF-Y is adipocyte specific, a ChIP assay of
preadipocyte and adipocyte was also performed. As shown
in Fig. 8C, C/EBP- and NF-YA occupied adiponectin
promoter in adipocytes but not in preadipocytes. These
results suggested that the drastic induction of adiponectin
expression during adipocyte differentiation might be ex-
plained by the recruitment of C/EBPs and NF-Y into the
adiponectin promoter. In addition, the glucose treatment
of differentiated adipocytes gave rise to the increased
C/EBP- and C/EBP- binding in the ChIP assay (Fig. 8D),
also suggesting that these transcription factors are in-
volved in the regulation of adiponectin gene expression in
response to nutritional status as well.
DISCUSSION
For many years, a number of studies have reported the
linkage between adiposity and insulin resistance. As it
became apparent that adipose tissue plays special roles for
body metabolism by secreting a set of molecules, recent
research has been focused on investigating how these
“adipokines” can act as link molecules between obesity
and insulin resistance (4). Adiponectin is one of the adipo-
kines secreted by fully differentiated adipocytes and thought
to be associated with some metabolic disease because
plasma adiponectin levels are decreased under conditions
of obesity and insulin resistance (10–12). Moreover, the
FIG. 6. 5 Deletion and mutation study of the
adiponectin promoter activity. A: Scheme for
5-deletion construct of adiponectin promoter.
B: 3T3-L1 cells were transiently transfected
with indicated adiponectin promoter-lucif-
erase construct (0.5 g) and pCMV--galacto-
sidase (0.1 g) 2 days after reaching
confluence. Cells were induced to differentiate
into adipocyte 4 h after transfection and har-
vested 72 h after transfection for luciferase
assay. C: C/EBP responsiveness of the deletion
constructs. 293T cells were transfected with
each construct in the presence or absence of
C/EBP- or C/EBP-. D: Mutation study of the
adiponectin promoter. Site-directed mutagen-
esis was performed to introduce the indicated
mutation into pGLB-A-134 plasmid, and each
construct was transfected into 293T cells with
or without C/EBP. Luciferase activities were
measured 48 h after transfection and normal-
ized by -galactosidase activity. Data repre-
sent means  SD of three independent
experiments.
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administration of adiponectin causes glucose-lowering ef-
fects and improves insulin resistance in mice (17,39,40).
Therefore, adiponectin is considered as an “insulin en-
hancer” linking adipose tissue and whole-body glucose
metabolism. In this regard, if adiponectin plays a role as
insulin enhancer, then it is likely that adiponectin could be
regulated to control body homeostasis by the changes of
metabolic stimulation such as the fasting-feeding cycle.
The present study clearly suggests that adiponectin is
regulated in response to nutrition. We showed that glucose
seemed to regulate adiponectin gene expression at the
transcriptional level (Fig. 1B). Most important, adiponec-
tin gene expression was induced in a relatively short
period (4–6 h) after refeeding of mice (Fig. 1C and D).
This finding in refed mice is interesting because several
studies have failed to show the relationship between the
adiponectin expression and fasting-refeeding cycle. It was
reported that adiponectin levels are relatively constant
and do not dramatically change postprandially in human
subjects (11). It is possible that the plasma adiponectin
levels might not represent acute changes of transcriptional
levels because adipocytokines may function as autocrine
or paracrine or the regulation at the protein level might
appear in the late period after diet. In addition, we cannot
exclude the possibility that the secretion pathway of the
adiponectin protein participates in another way of regula-
tion when the animals are subjected to a fasting-refeeding
cycle (41). Although the regulation observed in this study
cannot fully explain adiponectin biology, it is noteworthy
that the induction profile of the adiponectin gene transcrip-
tion (Fig. 1C) seemed to be similar to that of DNA-protein
binding on region AII on the promoter (Fig. 7). Thus, it is
likely that the expression of adiponectin is induced shortly
after feeding, at least at the transcription level.
The present study revealed that C/EBPs and NF-Y are
involved in the regulation of adiponectin gene expression.
C/EBP- and C/EBP- bound to the adiponectin gene in
in vitro and in vivo assays (Figs. 4 and 8) and activated
adiponectin promoter in vitro (Figs. 5 and 6). In addition,
NF-Y binds to the adiponectin promoter and plays a vital
role in regulation of adiponectin gene expression. It is
interesting that although transient transfection assays
showed that the adiponectin promoter was activated by
both C/EBP- and C/EBP-, the fold increase by C/EBP-
was larger than that by C/EBP- (Fig. 5), indicating that
C/EBP- had more crucial roles in regulation of adiponec-
tin expression than C/EBP-. In this regard, it should be
noted that a recently published study failed to show
C/EBP- responsiveness in the adiponectin promoter (42).
It is unclear why the C/EBP- response is small compared
with that of C/EBP-, despite its increased protein expres-
sion by nutritional status (Fig. 7C and D). One possible
explanation is that in our EMSA findings C/EBP- protein
alone could not lead to the fasting migrating band (Fig.
4B), which is apparent in natural nuclear extract from
white adipose tissue (Fig. 3). Meanwhile, the addition of
C/EBP- formed the fasting migrating band (Fig. 4B),
suggesting that C/EBP-, in association with C/EBP-,
plays an important role in the physiological regulation of
adiponectin expression. Moreover, we showed that both
FIG. 7. Binding activities of C/EBP and NF-Y on region AII of
adiponectin promoter were increased by diet intake. Rats were
fasted for 48 h and refed for the indicated time, and the nuclear
extracts of adipose tissue were prepared. A: EMSA of region AII.
120/70 oligonucleotides were incubated with 5 g of nuclear
extract of adipose tissue (left) or heat-treated nuclear extract
(right). Nuclear extracts were incubated at 72°C for 20 min for
denaturation of heat-labile protein before incubation with the
binding mixture. B: EMSA using nuclear extracts from glucose-
treated 3T3-L1 adipocytes. Differentiated 3T3-L1 adipocytes were
treated with glucose (27.5 mmol/l) for 0, 4, 12, and 24 h after
incubation in low glucose (5.5 mmol/l) for 24 h, and nuclear
extracts were prepared. C: Western blot (WB) analysis of nuclear
extracts from adipose tissue was performed using antibodies
against C/EBP-, C/EBP-, NF-YA, and Sp1. The same nuclear
extracts (15 g) used in EMSA were subjected to SDS-PAGE. D:
Western blot analysis of nuclear extracts from 3T3-L1 adipocytes
used in C, using antibodies against C/EBP-, C/EBP-, and histone
H3. WAT, white adipose tissue.
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C/EBP- and C/EBP- are important for adiponectin ex-
pression as shown by in vitro (EMSA) and in vivo (ChIP)
assays along with the overexpression study. Thus, it can
be concluded that C/EBP-, in association with C/EBP-
and/or NF-Y, has a role in the adiponectin gene expression.
As summarized in the introduction, C/EBP has been
identified as one of the major adipogenic factors control-
ling the transcription of the adipocyte-specific gene. The
regulation of C/EBP gene expression has been examined
in adipose tissue and liver. In liver cells, glucocorticoids
induced C/EBP- and C/EBP- at the level of transcription
and translation (43,44). Conversely, in adipose tissue,
glucocorticoids inhibited C/EBP- expression (45). Mean-
while, the effects of insulin on C/EBP- expression have
generally been shown to be inhibitory in adipose tissue
(46,47). In our study, C/EBP- and C/EBP- protein levels
were elevated in the refed state; thus, it is within the realm
of possibility that the elevated adiponectin mRNA level
from dietary nutrients is mediated by C/EBP- or C/EBP-.
The interaction between NF-Y and other transcription
factors on several gene promoters has been reported.
NF-Y is required for thyroid hormone regulation of liver
S14 gene transcription (48), and NF-Y also participated in
the regulation of the ATP citrate-lyase gene under the
control of SREBP1c (49). Although NF-Y is unlikely to be
regulated by metabolic status as shown in this study, it is
interesting to note that NF-Y is needed not only for basal
promoter activity but also for C/EBP responsiveness (Figs.
5 and 6). The region AII of the adiponectin promoter has
three potential binding sites for NF-Y (represented as m1,
m2, and m5 in Fig. 4); only mutation m5 abolished the
binding of NF-Y. Comparing this sequence with human
adiponectin gene, most nucleotides, including m4 and m5
but not m1/m2, were highly conserved between species
(Fig. 2). Therefore, we can conclude that NF-Y could be
another important regulator for the proper expression of
the adiponectin gene. In this regard, the binding of NF-Y
along with C/EBP might be required for adiponectin gene
expression during adipocyte differentiation as shown in
the ChIP assay (Fig. 8).
In summary, we found that transcription of adiponectin
is regulated by diet at the early stage of the refed state and
that C/EBP and NF-Y play roles in this process. It remains
to be clarified how the nutrients regulate these transcrip-
tion factors in adipose tissue. Also, whether the binding of
C/EBP or interaction with NF-Y is dysregulated in obesity
or insulin resistance must be investigated; however, it is
clear that C/EBP and NF-Y are important for the regulation
of the expression of adiponectin in response to nutrients
and in the course of adipocyte differentiation as well.
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